Crucial Update for Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR), Five Below, Inc. (NASDAQ: FIVE), Maison Solutions Inc. (NASDAQ: MSS), and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Looking into Claims for You
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Source: Globenewswire
Avantor, Inc. Investigation: Grabar Law Office is investigating claims against Avantor, Inc. for potential breaches of fiduciary duties by its officers and directors, following allegations of securities fraud related to misleading statements about the company's competitive position and operations.
Five Below, Inc. Class Action: A securities fraud class action against Five Below, Inc. has survived a motion to dismiss, with allegations that the company misled investors about its financial strength and operational challenges, allowing current shareholders to seek corporate reforms and potential returns.
Maison Solutions Inc. Class Action: An investigation into Maison Solutions Inc. is ongoing as a securities fraud class action has survived a motion to dismiss, with claims of misleading statements regarding the company's operations and related party transactions, now stayed pending settlement attempts.
Unicycive Therapeutics, Inc. Investigation: Grabar Law Office is also investigating Unicycive Therapeutics, Inc. for potential securities fraud, alleging that the company made false statements about its regulatory compliance and drug application prospects, with affected shareholders encouraged to seek corporate reforms.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like AVTR with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 12.30 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
2 Buy
9 Hold
2 Sell
Hold
Current: 11.050
Low
8.00
Averages
12.30
High
17.00
Current: 11.050
Low
8.00
Averages
12.30
High
17.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avantor Executives Under Investigation for Breach of Fiduciary Duties
- Fiduciary Duty Investigation: Kuehn Law, PLLC is investigating whether Avantor, Inc. executives breached their fiduciary duties to shareholders, with allegations that could impact corporate governance and shareholder confidence.
- False Competitive Positioning: A federal securities lawsuit claims insiders at Avantor failed to disclose that the company's competitive positioning was weaker than publicly represented, potentially leading to investor misjudgment regarding the company's prospects.
- Negative Competitive Pressures: Avantor is reportedly experiencing adverse effects from increased competition, and the failure to disclose this information may result in shareholder losses in investment decisions, affecting the company's stock performance.
- Shareholder Rights Protection: Kuehn Law urges shareholders to contact attorneys promptly to protect their rights, emphasizing the importance of participation, which could influence future shareholder litigation and corporate governance structures.
Continue Reading
Avantor (AVTR) Schedules Q4 2025 Earnings Release and Conference Call
- Earnings Release Schedule: Avantor will release its Q4 and full-year 2025 financial results before the market opens on February 11, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Timing: A conference call will take place on the same day at 8:00 a.m. Eastern Standard Time, aimed at providing in-depth discussions of the financial results to bolster market confidence.
- Webcast Availability: The session will be available via live audio webcast on Avantor's investor section, with a replay accessible for 30 days, ensuring that investors unable to attend live can still receive the information.
- Global Customer Base: Avantor serves over 300,000 customer locations in 180 countries, highlighting its leadership position in the life sciences and advanced technology sectors.
Continue Reading